Identifying Drug Repurposing Opportunities in Oncology
Stefania Orecchioni, Stefania Roma, Sara Raimondi, Sara Gandini, Francesco Bertolini · The Cancer Journal · 2019
The never-ending explosion in the cost of new oncology drugs is reducing in many countries the access to the most recent, effective anticancer therapies and represents a significant obstacle to the design and realization of combinatorial trials. Already approved, anticancer and nonanticancer drugs can be considered for in silico, preclinical, and clinical repurposing approaches and offer the significant advantages of a potentially cheaper, faster, and safer validation. This review discusses recent advances and challenges in the field.